Last reviewed · How we verify
imidafenacin, KRP-197/ONO-8025
imidafenacin, KRP-197/ONO-8025 is a Antimuscarinic Small molecule drug developed by Ono Pharmaceutical Co. Ltd. It is currently in Phase 3 development for Overactive bladder (urge urinary incontinence).
Imidafenacin is an antimuscarinic agent that acts as a selective M3 receptor antagonist.
Imidafenacin is an antimuscarinic agent that acts as a selective M3 receptor antagonist. Used for Overactive bladder (urge urinary incontinence).
At a glance
| Generic name | imidafenacin, KRP-197/ONO-8025 |
|---|---|
| Sponsor | Ono Pharmaceutical Co. Ltd |
| Drug class | Antimuscarinic |
| Target | M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
By blocking the M3 receptor, imidafenacin reduces bladder contractions and decreases the frequency of urge urinary incontinence episodes. This mechanism of action is specific to the M3 receptor subtype, which is primarily responsible for bladder contractions. As a result, imidafenacin provides targeted relief for patients with overactive bladder symptoms.
Approved indications
- Overactive bladder (urge urinary incontinence)
Common side effects
- Dry mouth
- Constipation
- Headache
Key clinical trials
- Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan (PHASE2)
- Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan (PHASE3)
- Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- imidafenacin, KRP-197/ONO-8025 CI brief — competitive landscape report
- imidafenacin, KRP-197/ONO-8025 updates RSS · CI watch RSS
- Ono Pharmaceutical Co. Ltd portfolio CI
Frequently asked questions about imidafenacin, KRP-197/ONO-8025
What is imidafenacin, KRP-197/ONO-8025?
How does imidafenacin, KRP-197/ONO-8025 work?
What is imidafenacin, KRP-197/ONO-8025 used for?
Who makes imidafenacin, KRP-197/ONO-8025?
What drug class is imidafenacin, KRP-197/ONO-8025 in?
What development phase is imidafenacin, KRP-197/ONO-8025 in?
What are the side effects of imidafenacin, KRP-197/ONO-8025?
What does imidafenacin, KRP-197/ONO-8025 target?
Related
- Drug class: All Antimuscarinic drugs
- Target: All drugs targeting M3 receptor
- Manufacturer: Ono Pharmaceutical Co. Ltd — full pipeline
- Therapeutic area: All drugs in Urology
- Indication: Drugs for Overactive bladder (urge urinary incontinence)
- Compare: imidafenacin, KRP-197/ONO-8025 vs similar drugs
- Pricing: imidafenacin, KRP-197/ONO-8025 cost, discount & access